Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials
2024

Delgocitinib Ointment for Atopic Dermatitis in Children

Sample size: 240 publication Evidence: moderate

Author Information

Author(s): Tatsuki Fukuie, Hiroyuki Toyama, Mai Tanaka, Katsuyo Ohashi-Doi, Kenji Kabashima

Primary Institution: National Center for Child Health and Development, TORII Pharmaceutical Co Ltd, Graduate School of Medicine Kyoto University

Hypothesis

The study aims to compare the efficacy and safety of two doses of delgocitinib ointment in children with atopic dermatitis.

Conclusion

Delgocitinib 0.5% ointment may be more effective than the 0.25% dose for mild atopic dermatitis, and it is well tolerated when used in combination with other treatments.

Supporting Evidence

  • The cumulative investigator's global assessment showed higher effectiveness for the 0.5% ointment in mild cases.
  • No significant differences in safety profiles were observed between the two doses.
  • Delgocitinib ointment was well tolerated when used with other medications.

Takeaway

This study looked at a cream called delgocitinib to help kids with skin problems. They found that a stronger version of the cream worked better for kids with less severe skin issues.

Methodology

Post-hoc analysis of data from two double-blind placebo-controlled trials comparing 0.25% and 0.5% delgocitinib ointment in pediatric patients with atopic dermatitis.

Limitations

The study is based on post-hoc analyses of short-term treatment data from a relatively small number of patients.

Participant Demographics

Participants were children aged 2 to 15 years with atopic dermatitis.

Digital Object Identifier (DOI)

10.1111/ped.15798

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication